

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD. and BIOCON BIOLOGICS INC.,
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 10,888,601

Inter Partes Review No. IPR2023-00739¹

PATENT OWNER'S UPDATED EXHIBIT LIST

¹ IPR2024-00201 has been joined with IPR2023-00739.

Updated Exhibit List

Exhibit Description	Exhibit #
U.S. 10,888,601 Patent Disclaimer (July 11, 2022)	2001
U.S. 10,888,601 Patent Disclaimer (July 25, 2023)	2002
Jean-Francois Korobelnik et al., <i>Intravitreal Aflibercept for Diabetic Macular Edema</i> , 121 OPTHALMOLOGY 2247 (2014)	2003
LUCENTIS® Label (rev. Aug. 2012)	2004
Declaration of David M. Brown, M.D., <i>Mylan Pharms. Inc. v. Regeneron Pharms., Inc.</i> , IPR2021-00880, Ex.2050 (Feb. 10, 2022)	2005
Prema Abraham et al., <i>Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 AM. J. OPTHALMOLOGY 315 (2010)	2006
<i>Retinal Physician Symposium Covers Broad Range of Topics</i> , Retinal Physician (Sept. 1, 2006), https://www.retinalphysician.com/issues/2006/september-2006/retinal-physician-symposium-covers-broad-range-of .	2007
DME and VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] Investigation of Clinical Impact (DA VINCI), https://classic.clinicaltrials.gov/ct2/show/study/NCT00789477	2008
Trial Transcript (unsealed portions), <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.)	2009
Press Release, Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication (Dec. 18, 2013)	2010
Provisional Application No. 61/432,245 (Jan. 13, 2011)	2011
Mylan Pharmaceuticals Inc.'s Answer, Defenses, and Counterclaims to Plaintiff's Complaint, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 47 (filed Aug. 25, 2022)	2012

Exhibit Description	Exhibit #
Complaint for Patent Infringement, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 1 (filed Aug. 2, 2022)	2013
Order on Claim Construction, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 427 (filed Apr. 19, 2023)	2014
Scheduling Order, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 87 (filed Oct. 25, 2022)	2015
Regeneron’s Stipulation Regarding Summary Judgment and Case Narrowing, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 433 (filed Apr. 27, 2023)	2016
Stipulation and Order Joining Biocon Biologics Inc. as Defendant, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 523 (filed June 5, 2023)	2017
Defendant’s Opening Post Trial Brief - Issues Where Defendants Bear the Burden of Proof, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 576 (filed July 7, 2023)	2018
Order Setting Briefing Schedule, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 514 (filed May 30, 2023)	2019
Transcript of the Status Conference held on Sept. 28, 2022, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 90 (filed Nov. 2, 2022)	2020
Irene Barbazetto et al., <i>Dosing Regimen and The Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab</i> , 30 RETINA 1376 (2010)	2021
Michael Engelbert et al., <i>The “Treat and Extend” Dosing Regimen of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration</i> (June 2010) www.visioncareprofessional.com/emails/amdupdate/index42.htm	2022

Exhibit Description	Exhibit #
David S. Boyer et al., <i>A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration</i> , 116 OPTHALMOLOGY 1731 (2009)	2023
Declaration of Kira A. Davis in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Davis Decl.”).	2024
Declaration of Daralyn J. Durie in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Durie Decl.”)	2025
Default Protective Order	2026
Declaration of Michael W. Stewart, M.D.	2027
Curriculum Vitae of Michael W. Stewart, M.D.	2028
Deposition Transcript of Edward Chaum, M.D., Ph.D. (January 5, 2024)	2029
Drugs@FDA, AVASTIN™ Label, 2/2004, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125085lbl.pdf	2030
AVASTIN Approval Letter (February 26, 2004)	2031
A Study of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE), NCT00473330, ClinicalTrials.gov (Version 9, November 11, 2010), https://www.clinicaltrials.gov/ct2/show/NCT00473330	2032
Genentech Press Release, <i>FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States</i> , (April 17, 2017)	2033

Exhibit Description	Exhibit #
Drugs@FDA, LUCENTIS® Label, 4/2017, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf	2034
Declaration of David M. Brown, M.D.	2035
Curriculum Vitae of David M. Brown, M.D.	2036
EYLEA Supplement Approval Letter (March 25, 2015)	2037
EYLEA Supplement Approval Letter (May 13, 2019)	2038
Judgment in Civil Action, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 665 (filed Dec. 27, 2023)	2039
U.S Patent No. 11,730,794 to Yancopoulos	2040
Geeta A. Lalwani et al., A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: year 2 of the PrONTO Study. <i>American journal of ophthalmology</i> , 148(1), 43-58 (2009)	2041
F.G. Holz et al., SUSTAIN Study Group. Safety and Efficacy of Ranibizumab Treatment in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Results of the SUSTAIN Study. <i>Investigative Ophthalmology & Visual Science</i> , 50(13), 3095-3095 (2009)	2042
Declaration of Richard Manning, Ph.D. – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2043
Sarah Whelan, <i>What is Angiogenesis?</i> , Technology Networks (July 6, 2022)	2044

Exhibit Description	Exhibit #
Matthew Dombrow et al., <i>Ocular Angiogenesis: The Science Behind the Symptoms</i> , Retinal Physician (2011)	2045
Joan W. Miller, VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. <i>Translational vision science & technology</i> , 5(2), 9-9 (2016)	2046
Macugen Approval Letter (December 14, 2004)	2047
Press Release, Genentech, <i>FDA Approves Genentech's Lucentis (Ranibizumab Injection) Prefilled Syringe</i> (October 14, 2016)	2048
Diana V. Do et al., One-Year Outcomes of the Da Vinci Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. <i>Ophthalmology</i> , 119(8), 1658-1665 (2012)	2049
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) (RIDE), NCT00473382, ClinicalTrials.gov, https://www.clinicaltrials.gov/study/NCT00473382	2050
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) (BRAVO), NCT00486018, ClinicalTrials.gov, https://www.clinicaltrials.gov/study/NCT00486018	2051
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (CRUISE), NCT00485836, ClinicalTrials.gov, https://www.clinicaltrials.gov/study/NCT00485836	2052
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO), NCT00943072, ClinicalTrials.gov, https://www.clinicaltrials.gov/study/NCT00943072	2053

Exhibit Description	Exhibit #
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (GALILEO), NCT01012973, ClinicalTrials.gov, https://www.clinicaltrials.gov/study/NCT01012973	2054
Press Release, Genentech, <i>Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration</i> (December 30, 2005)	2055
Macugen (pegaptanib sodium injection) label submitted with NDA 21-756	2056
Diabetic Retinopathy Clinical Research Network, A Phase 2 Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema. <i>Ophthalmology</i> , 114(10), 1860-1867 (2007)	2057
Michael Michaelides et al., A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT study): 12-month data: report 2. <i>Ophthalmology</i> , 117(6), 1078-1086 (2010)	2058
Pascale Massin et al., Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) A 12-month, randomized, controlled, double-masked, multicenter phase II study. <i>Diabetes Care</i> , 33(11), 2399-2405 (2010)	2059
Paul Mitchell et al., The RESTORE study: Ranibizumab Monotherapy or Combined with Laser Versus Laser Monotherapy for Diabetic Macular Edema. <i>Ophthalmology</i> , 118(4), 615-625 (2011)	2060
Quan Dong Nguyen et al., Two-year Outcomes of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. <i>Ophthalmology</i> , 117(11), 2146-2151 (2010)	2061
David M. Brown et al., <i>Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration</i> , 355 N. Eng. J. Med. 1432 (2006)	2062

Exhibit Description	Exhibit #
Press Release, <i>Genentech, Inc. Submits Biologics License Application for FDA Review of Lucentis(TM) In Wet Age-Related Macular Degeneration</i> (Dec. 30, 2005), https://www.biospace.com/article/releases/genentech-inc-submits-biologicslicense- application-for-fda-review-of-lucentis-tm-in-wet-age-related-maculardegeneration-/	2063
Jonathan P. Levine et al., <i>Macular Hemorrhage in Neovascular Age-Related Macular Degeneration After Stabilization with Antiangiogenic Therapy</i> , 29 Retina 1074 (2009)	2064
Daniele Cruz, <i>PIER Data Suggest a Need for Tailored Injection Schedule</i> , Ocular Surgery News, (Sept. 1, 2006), https://www.healio.com/news/ophthalmology/20120331/pier-data-suggest-a-need-for-tailored-injection-schedule	2065
Press Release, Genentech, <i>FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration</i> (June 30, 2006)	2066
United States Patent and Trademark Office, Manual of Patent Examining Procedure, Ninth Edition, Revision: 7/2010, 716.03 I and 716.03(b)	2067
Rahul Guha et al. (2009), “The Economics of Commercial Success in Pharmaceutical Patent Litigation,” <i>Landslide</i> 1(5))	2068
Regeneron Website, History, https://www.regeneron.com/about/history (accessed 1/15/2024)	2069
Drugs@FDA, Eylea Label, 11/2011, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf	2070
Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2071

Exhibit Description	Exhibit #
Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2072
Regeneron, Eylea Sales Summary, c.2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2073
Intentionally Left Blank	2074
Drugs.com Website, Eylea FDA Approval History, https://www.drugs.com/history/eylea.html (accessed 1/15/2024)	2075
Regeneron Press Release, “Eylea Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME),” 7/29/2014, https://investor.regeneron.com/news-releases/news-release-details/eylear-afibercept-injection-receives-fda-approval-treatment	2076
NCI, Second-Line Therapy, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/second-line-therapy (accessed 1/16/2024)	2077
Regeneron, “Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 1/29/2021 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2078
Richard Manning et al., “Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?” <i>International Journal of the Economics of Business</i> 22(2): 231–243 (2015)	2079
Centers for Disease Control and Prevention, “Vision Loss: A Public Health Problem,” 12/19/2022, https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm	2080
World Health Organization, “Blindness and Vision Impairment Fact Sheet,” 8/10/2023, https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment	2081

Exhibit Description	Exhibit #
American Society of Retina Specialists, “2009 Preferences and Trends Membership Survey,” c. 2009 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2082
Regeneron, “DME Market Assessment,” 8/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2083
American Society of Retina Specialists, “2015 Preferences and Trends (PAT) Survey,” c. 2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2084
American Society of Retina Specialists, “2016 Preferences and Trends (PAT) Survey,” c. 2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2085
Regeneron, “Q4 2018 Performance Update Wet AMD, DME, & MEfRVO“, 2/2019	2086
Regeneron, “Q2 2020 Performance Update,” 7/2020	2087
P Mitchell et al., <i>Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials</i> , 94 BRIT. J. OPHTHALMOLOGY 2 (2009) (date of online publication)	2088
Donald S. Fong et al., <i>Diabetic Retinopathy</i> , Diabetes care, 27 (10), 2540-2553 (2004)	2089
Wei Wang et al., <i>Diabetic Retinopathy: Pathophysiology and Treatments</i> , International Journal of Molecular Sciences, 19(6), 1816 (2018)	2090
Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. <i>Ophthalmology</i> , 98(5), 823-833 (1991)	2091
David M. Brown et al., Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results	2092

Exhibit Description	Exhibit #
from the PANORAMA randomized clinical trial. <i>JAMA ophthalmology</i> , 139(9), 946-955 (2021)	
Annie Chan, MD, et al., Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. <i>Archives of ophthalmology</i> , 124(2), 193-198 (2006)	2093
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. <i>Ophthalmology</i> , 98(5), 766-785 (1991)	2094
Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. <i>Ophthalmology</i> , 88(7), 583-600 (1981)	2095
Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products —Content and Format. Food and Drug Administration (July 2018)	2096
Ovidiu Musat et al., Diabetic macular edema. <i>Romanian journal of ophthalmology</i> , 59(3), 133 (2015)	2097
Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Early treatment diabetic retinopathy study research group. <i>Arch Ophthalmol</i> , 103(12), 1796-1806 (1985)	2098
Anita Prasad, The DRCR Network Aids DR Treatment, <i>Review of Ophthalmology</i> (2006)	2099
Pedro Romero-Aroca et al., Laser treatment for diabetic macular edema in the 21st century. <i>Current diabetes reviews</i> , 10(2), 100-112 (2014)	2100
Lucentis Supplement Approval Letter (April 15, 2017)	2101
JF Arevalo et al., Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. <i>Eye</i> , 23(1), 117-123 (2009)	2102

Exhibit Description	Exhibit #
Ravi Parikh et al., Trends Of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. <i>Ophthalmology</i> , 124(3), 352-358 (2017)	2103
Richard F. Spaide and Yale L. Fisher, Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. <i>Retina</i> , 26(3), 275-278 (2006)	2104
V.H. Gonzalez et al., Use of Pegaptanib Sodium (Macugen®) for the Regression of Proliferative Diabetic Retinopathy. <i>Investigative Ophthalmology & Visual Science</i> , 47(13), 2329-2329 (2006)	2105
Drugs@FDA, Eylea label, 2/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s0751bl.pdf	2106
Regeneron Pharmaceuticals, Inc., Form 10-K, for the fiscal year ended December 31, 2020	2107
Drugs@FDA, Lucentis Label, c. 2006, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/1251561bl.pdf .	2108
Drugs@FDA, Beovu label, 10/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s0001bl.pdf .	2109
Drugs@FDA, Susvimo Label, 10/2021, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s0001bl.pdf	2110
Drugs@FDA, Vabysmo Label, 1/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s0001bl.pdf .	2111
Drugs@FDA, Lucentis Label, 6/2010, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s0531bl.pdf .	2112
Drugs@FDA, Eylea Label, 10/2014, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s0431bl.pdf	2113

Exhibit Description	Exhibit #
Drugs@FDA, Lucentis Label, 8/2012, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf	2114
Drugs@FDA, Eylea label, 5/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf	2115
Drugs@FDA, Lucentis label, 3/2018, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf	2116
Drugs@FDA, Beovu label, 12/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf	2117
Drugs@FDA, Susvimo Label, 4/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761197s002lbl.pdf	2118
Drugs@FDA, Vabysmo Label, 1/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf	2119
Regeneron, “US Eylea P&L LTD,” 12/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2120
Intentionally Left Blank	2121
Intentionally Left Blank	2122
Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service (accessed 1/16/2024)	2123

Exhibit Description	Exhibit #
Regeneron, “Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME,” 9/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2124
Regeneron, ATU Sales Share Data: All Indications, c. 2021	2125
Regeneron, ATU Sales Share Data: Wet AMD, c. 2021	2126
Regeneron, ATU Sales Share Data: DME, c. 2021	2127
Regeneron, ATU Sales Share Data: CRVO, c. 2021	2128
Regeneron, ATU Sales Share Data: BRVO, c. 2021	2129
Regeneron, ATU Sales Share Data: DR w/o DME, c. 2021	2130
Intentionally Left Blank	2131
Intentionally Left Blank	2132
Intentionally Left Blank	2133
Intentionally Left Blank	2134
Intentionally Left Blank	2135

Exhibit Description	Exhibit #
Intentionally Left Blank	2136
Intentionally Left Blank	2137
Intentionally Left Blank	2138
Intentionally Left Blank	2139
Intentionally Left Blank	2140
Intentionally Left Blank	2141
Intentionally Left Blank	2142
Regeneron, “DME Market Assessment, Benchmark Wave,” 11/8/2013 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2143
Regeneron, “DME Market Assessment Q1 2017,” 5/2017 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2144
Regeneron, “DME Market Assessment Wave 3, Q3 2014,” 11/2014 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2145
Regeneron, “DME Market Assessment Q4 2014,” 1/2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2146

Exhibit Description	Exhibit #
Regeneron, “DME Market Assessment Q1 2015,” 4/2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2147
Regeneron, “DME Market Assessment Q2 2015,” 8/2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2148
Regeneron, “DME Market Assessment Q3 2015,” 11/2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2149
Regeneron, “DME Market Assessment Q4 2015,” 2/2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2150
Regeneron, “DME Market Assessment Q1 2016,” 4/2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2151
Regeneron, “DME Market Assessment Q2 2016,” 8/2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2152
Regeneron, “DME Market Assessment Q3 2016,” 10/2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2153
Regeneron, “DME Market Assessment Q4 2016,” 1/2017 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2154
Regeneron, “DME Market Assessment Q2 2017,” 7/2017 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2155
Regeneron, “DME Market Assessment Q3 2017,” 10/2017 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2156
Regeneron, “DME Market Assessment Q4 2017,” 2/2018 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2157

Exhibit Description	Exhibit #
Regeneron, “DME Market Assessment Q1 2018,” 5/2018 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2158
Regeneron, “DME Market Assessment Q2 2018,” 7/2018 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2159
Regeneron, “Q3 2018 Performance Update Wet AMD, DME, & MEfRVO,” 11/2018 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2160
Drugs@FDA, Eylea label, 9/2012, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf	2161
Regeneron, “Q1 2019 Performance Update Wet AMD, DME, & MEfRVO,” 5/2019 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2162
Regeneron, “Q2 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 8/2019 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2163
Regeneron, “Q3 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 11/2019 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2164
Regeneron, “Q4 2019 Performance Update Wet AMD, DME, & MEfRVO,” 1/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2165
Regeneron, “Q1 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 4/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2166
Regeneron, “Q2 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 7/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2167
Regeneron, “Q3 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 11/2020 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER	2168

Exhibit Description	Exhibit #
Supplemental Declaration of Michael W. Stewart, M.D.	2169 [SERVED]
How to Read a Study Record, ClinicalTrials.gov, available at https://clinicaltrials.gov/study-basics/how-to-read-study-record#record-history-tab (last updated Jan. 9, 2024).	2170 [SERVED]
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE), NCT00473330, ClinicalTrials.gov, https://www.clinicaltrials.gov/ct2/show/NCT00473330 ; archived by <i>Wayback Machine</i> at https://web.archive.org/web/20100609131649/https://www.clinicaltrials.gov/ct2/show/NCT00473330 ; citing a capture dated June 9, 2010.	2171 [SERVED]
Sarah Whelan, What is Angiogenesis?, Technology Networks (Jul. 6, 2022)	2172 [SERVED]
Thomas H. Adair & Jean-Pierre Montani, Angiogenesis (2011)	2173 [SERVED]
Michael J. Tolentino et al., Intravitreal Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate, <i>Ophthalmology</i> , 103(11), 1820-1828 (1996)	2174 [SERVED]
Declaration of Nathaniel E. Frank-White, Internet Archive, regarding https://web.archive.org/web/20100609131649/https://www.clinicaltrials.gov/ct2/show/NCT00473330	2175 [SERVED]
Declaration of Matthew M. Wilk in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Wilk Decl.”).	2176 [NEW]
Declaration of Jeremy Cobb in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Cobb Decl.”).	2177 [NEW]

IPR2023-00739

Date: March 15, 2024

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S UPDATED EXHIBIT LIST was served on the date listed below via email (by agreement) upon the following counsel of record for Petitioners.

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Elliot Choi (*pro hac vice* conditionally granted)
Zachariah Summers (*pro hac vice* conditionally granted)
Sarah Cork (*pro hac vice* to be applied for)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART & SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
General Tel: (212) 849-7000
Direct Tel: (212) 849-7322
Fax: (212) 849-7100
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
elliotchoi@quinnemanuel.com
zachsummers@quinnemanuel.com
landonsmith@quinnemanuel.com
qe-samsungbioepis@quinnemanuel.com

Paul J. Molino (Reg. No. 45,350)
William A. Rakoczy (*pro hac vice* to be filed)
Deanne M. Mazzochi (Reg. No. 50,158)
Heinz J. Salmen (*pro hac vice* to be filed)
Jeff A. Marx (Reg. No. 56,977)
Eric R. Hunt (*pro hac vice* to be filed)
Neil B. McLaughlin (Reg. No. 70,810)
Lauren M. Lesko (*pro hac vice* to be filed)
L. Scott Beall (Reg. No. 52,601)
Thomas H. Ehrich (Reg. No. 67,122)
Steven J. Birkos (Reg. No. 65,300)
Jake R. Ritthamel (*pro hac vice* to be filed)

IPR2023-00739

Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard Street
Chicago, IL 60654
Telephone: (312) 527-2157
Facsimile: (312) 843-6260
MYL REG IPR@rmmslegal.com

Dated: March 15, 2024

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287